Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

@article{Yang2008PrevalenceOB,
  title={Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma},
  author={David T Yang and Ken H. Young and Brad S. Kahl and Stephanie Markovina and Shigeki Miyamoto},
  journal={Molecular Cancer},
  year={2008},
  volume={7},
  pages={40 - 40}
}
BackgroundThe proteasome inhibitor bortezomib can inhibit activation of the transcription factor NF-κB, a mechanism implicated in its anti-neoplastic effects observed in mantle cell lymphoma (MCL). However, NF-κB can be activated through many distinct mechanisms, including proteasome independent pathways. While MCL cells have been shown to harbor constitutive NF-κB activity, what fraction of this activity in primary MCL samples is sensitive or resistant to inhibition by bortezomib remains… Expand
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
TLDR
This study is the first to show the expression of TG2 and the contribution ofTG2 to NF-κB signaling in MCL cells, and TG2 inhibition may be used as an alternative target anti-MCL therapy, and calcium blockers may be combined with bortezomib to overcome the bortzomib resistance in M CL. Expand
PRDM1 Is Required for Mantle Cell Lymphoma Response to Bortezomib
TLDR
Ch Chromatin immunoprecipitation and knockdown studies reveal that specific repression of MKI67 and PCNA is mediated by PRDM1 in response to bortezomib, and promoter studies and mutation/deletion analysis show thatPRDM1 functions through specific sites in the PCNA proximal promoter and an MKI 67 distal upstream repression domain. Expand
The NF-κB pathway is rarely spontaneously activated in mantle cell lymphoma (MCL) cell lines and patient's samples.
TLDR
Data suggest that NF-κB does not play a key role in proliferation and apoptotic processes in MCL cell lines, and in patient samples, the presence of p65 in the nucleus reflecting NF-σκB activation is rare but associated with a poor outcome. Expand
Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach
TLDR
Results suggest that 13-197 as a single agent disrupts the NF-κB and mTOR pathways leading to suppression of proliferation and increased apoptosis in malignant MCL cells including reduction in tumor burden in mice. Expand
Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma
TLDR
Investigation of the redox-sensitive intracellular mechanism that might play a critical role in bortezomib response in MCL cells demonstrated that BACH2 was translocated to the nucleus in response to bortzomib and induced apoptotic responses through the modulation of anti-oxidative and anti-apoptotic genes. Expand
Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
TLDR
This article is the first to show that stem-like MCL cells utilize constitutive NF-κB expression for survival, and it will be important to find alternative therapeutic strategies to inhibit NF- KakB expression. Expand
Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
TLDR
CDK4 activity in MCL is critical for NOXA stabilization upon treatment with UPS inhibitors allowing preferential induction of cell death in cyclin D transformed cells and the fatty acid synthase inhibitor orlistat is identified to be an efficient autophagy inhibitor when used in combination with bortezomib. Expand
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
TLDR
It is concluded that plasmacytic differentiation in the absence of an increased secretory load can enable cells to withstand the stress of proteasome inhibition. Expand
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
TLDR
It is argued that AML might be rendered sensitive to proteasome inhibitors by cotreatment with either an Nrf2-inhibitory or Bach1-in inhibitory treatment, rationalizing a targeted therapy against AML. Expand
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production
TLDR
Findings indicate that verapamil could be used to increase the cell cytotoxicity of bortezomib, and synergistic cytotoxic effects of the combined regimens were analysed by combination index plots. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 118 REFERENCES
Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis1
TLDR
It is suggested that constitutive NF-κB expression plays a key role in the growth and survival of MCL cells, and that PS-341 and BAY 11 may be useful therapeutic agents for MCL, a lymphoma that is refractory to most current chemotherapy regimens. Expand
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
TLDR
Noxa RNA interference markedly decreased sensitivity to bortezomib, pointing to this protein as a key mediator between proteasome inhibition and mitochondrial depolarization in MCL cells, suggesting that up-regulation of Noxa might counteract Mcl-1 accumulation after bortzomib treatment. Expand
Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
TLDR
Curcumin inhibits the constitutive NF-kappaB and IKK leading to suppression of expression of NF- kappaB-regulated gene products that results in the suppression of proliferation, cell cycle arrest, and induction of apoptosis in MCL. Expand
Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas
TLDR
The findings indicate that constitutive NF-κB and NFAT activations are crucial transcriptional regulators of the BLyS survival pathway in malignant B cells that could be therapeutic targets in aggressive NHL-B. Expand
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
TLDR
The molecular sequelae of PS-341 treatment in MM cells are characterized and the rationale for future clinical trials of this promising agent, in combination with conventional and novel therapies, to improve patient outcome in MM is explained. Expand
Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.
TLDR
The findings indicate that constitutive NF-kappaB and NFAT activations are crucial transcriptional regulators of the BLyS survival pathway in malignant B cells that could be therapeutic targets in aggressive NHL-B. Expand
Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells
TLDR
Findings establish the NF-κB pathway as a new molecular target for drug development in the most clinically intractable subtype of DLBCL and demonstrate that the twoDLBCL subtypes defined by gene expression profiling utilize distinct pathogenetic mechanisms. Expand
NF-κB1 Can Inhibit v-Abl-Induced Lymphoid Transformation by Functioning as a Negative Regulator of Cyclin D1 Expression
TLDR
It is shown that the proliferation and tumorigenicity of Abelson murine leukemia virus (A-MuLV)-transformed pre-B cells are enhanced in the absence of NF-κB1 and that this coincides with elevated levels of cyclin D1. Expand
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
TLDR
Molecular mechanisms whereby PS-341 mediates anti-MM activity are demonstrated by inducing p53 and MDM2 protein expression; inducing the phosphorylation (Ser15) of p53 protein; activating c-Jun NH(2)-terminal kinase (JNK), caspase-8, and caspases-3; and cleaving the DNA protein kinase catalytic subunit, ATM, andMDM2. Expand
NF-κB and IKK as therapeutic targets in cancer
TLDR
Experimental data indicate that NF-κB can play a tumor suppressor role in certain settings and that it can be important in promoting an apoptotic signal downstream of certain cancer therapy regimens, which indicates thorough approaches must be initiated to determine the molecular mechanisms that dictate the complexity of oncologic and therapeutic outcomes that are controlled by NF-β. Expand
...
1
2
3
4
5
...